These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9389813

  • 1. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.
    Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C.
    Fertil Steril; 1997 Nov; 68(5):844-50. PubMed ID: 9389813
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 6. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 7. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.
    Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E.
    Andrology; 2017 May; 5(3):516-526. PubMed ID: 28189123
    [Abstract] [Full Text] [Related]

  • 8. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [Abstract] [Full Text] [Related]

  • 9. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [Abstract] [Full Text] [Related]

  • 10. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
    McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
    [Abstract] [Full Text] [Related]

  • 11. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [Abstract] [Full Text] [Related]

  • 12. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 13. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [Abstract] [Full Text] [Related]

  • 14. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 15. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.
    Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY.
    J Clin Endocrinol Metab; 2003 Feb; 88(2):562-8. PubMed ID: 12574181
    [Abstract] [Full Text] [Related]

  • 16. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 17. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 18. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J.
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [Abstract] [Full Text] [Related]

  • 19. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men.
    Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J, Yang PJ, Gao ES.
    J Androl; 2004 Apr; 25(5):720-7. PubMed ID: 15292101
    [Abstract] [Full Text] [Related]

  • 20. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.